Blood levels of furazolidone in patients on anti-H. pylori therapy

Coelho, Luiz G.; Calafatti, Silvana A.; Vieira, Washington L.; Barros, Rita S.; Casaes, Polyana E.; Morais, Rosana B.; Borges, Julienne M.; Fernandes, Maria L.; Ortiz, Rodrigo M.; Pedrazzoli, José; Castro, Luiz Fernando Andrade de

doi:10.1016/s0016-5085(00)80728-3

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug acts by inhibiting bacterial enzymes, mainly those involved in the Krebs cycle. It is poorly absorbed and occurs in plasma 1 h after ingestion, with a maximum absorption peak being observed within the first 4 h 27, 28 . Reports of strains resistant to furazolidone are rare.…”

Section: Discussionmentioning

confidence: 99%

New once‐daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study

Coelho

Moretzsohn

Vieira

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Helicobacter pylori treatment failure is a growing problem in daily practice. Aim: To determine the efficacy of the combination of rabeprazole, levofloxacin and furazolidone as a rescue therapy. Methods: Duodenal ulcer patients previously submitted, without success, to at least two H. pylori treatment regimens were included. Gastroscopy (urease test, histological examination and culture) and 13 C-urea

show abstract

Section: Discussionmentioning

confidence: 99%

New once‐daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study

Coelho

Moretzsohn

Vieira

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…55,62 Triple regimens consisting of bismuth compound (subsalicylate or colloidal bismuth subcitrate) + F + one other antibiotic, without PPI or H2-receptor antagonists, obtained a significantly higher PER (P = 0.0002) than the PPI-based triple regimens (Table 1). 30,31,38,[56][57][58][59]61,65,75 Quadruple regimens given as primary treatment are more efficient than the standard triple regimens (P = 0.01; Table 1). 37,46,[60][61][62]66 Other therapies Furazolidone monotherapy, administered for 3-4 weeks, was efficient in 60-80% of the cases; 20,21,75,77 however, a rapid recolonization was observed in one study.…”

Section: Primary Treatment and Triple Therapiesmentioning

confidence: 99%

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Buzás¹,

Józan

2007

J of Gastro and Hepatol

View full text Add to dashboard Cite

Several aspects of Helicobacter pylori eradication have been meta-analyzed; however, nitrofuran-based therapies constitute an exception. The aim of this study was the systematic review and meta-analysis of the effect of furazolidone-and nitrofurantoin-based regimens in the eradication of infection. Studies evaluating the effects of nitrofurans on H. pylori were identified from Medline, EMBASE, the Cochrane Controlled Trials Register and congress abstracts. The studies were classified into groups based on first-, second-and third-line regimens. The pooled eradication rates and combined odd ratios of the individual studies were calculated and compared with the published meta-analysis. The factors influencing the efficiency of the regimens were also analyzed. Side-effects of nitrofuranbased regimens were also analyzed. The pooled eradication rate of primary proton pump inhibitor-based regimens containing furazolidone was 76.3% .2). The odds ratio for furazolidone-based regimens versus standard triple therapies was 2.34 (CI 0.76-3.92). Ranitidine bismuth citrate + furazolidone-based triple regimens were equally efficient (83.5%, CI 74.0-93.0, P = 0.06 versus triple therapies). Schedules including a H2 antagonist + furazolidone + one other antibiotic achieved pooled eradication rates of 79.9% (CI 67.8-89.9, P = 0.04). Bismuth-based triple therapies achieved 84.5% (CI 72.6-93.0, P = 0.002). Primary quadruple regimens containing furazolidone were superior to triple therapies (83.4%, CI 69.7-92.3, P = 0.01). Second-line schedules containing furazolidone obtained eradication rates of 76.1% (CI 66.4-85.0, P = 0.28 versus primary regimens). Third-line 'rescue' therapies were efficient in 65.5% of the cases (CI 56.3-75.5, P = 0.0001). Side-effects of the regimens containing furazolidone were more frequent than in standard therapies (P = 0.02). The combined odds ratio of side-effects for furazolidonebased versus standard therapies was 0.74 (CI 0.32-1.98). The duration of treatment, but not the furazolidone dose, influenced the treatment outcome. Primary triple regimens containing furazolidone are slightly less efficient than the standard primary combinations; primary quadruple regimens were more efficient than triple therapies. Furazolidone is also efficient as a component of second-line or rescue therapies.

show abstract

Blood levels of furazolidone in patients on anti-H. pylori therapy

Cited by 2 publications

References 0 publications

New once‐daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study

New once‐daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Contact Info

Product

Resources

About